Ashish Bansal

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial”.

Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(25)00044-x

N/A

0.829DataRank · unranked

24 citations

Nicola A. Hanania, Surya P. Bhatt, Mona Bafadhel, Klaus F. Rabe, Claus Vogelmeier +11 more

Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS

CHEST Journal(2025)10.1016/j.chest.2025.01.029

N/A

0.421DataRank · unranked

13 citations

Klaus F. Rabe, Nicola A. Hanania, Claus Vogelmeier, Mona Bafadhel, Stephanie A. Christenson +11 more